Can U.S. Citizens Buy Prescription Drugs From Canada?

The five answers at a glance

Question	Short answer
Is personal importation legal?	Generally no for foreign unapproved drugs; limited FDA discretion is not legalization
Is there a 90-day exception?	No blanket exception; quantity is one factor in a discretionary policy
Will Canadian pharmacies stop shipping?	Industry predicts major disruption after October 22; the official rule does not declare a universal drug ban
Will U.S. insurance pay?	Usually not directly; reimbursement depends on the plan and may be denied
How can a buyer check a pharmacy?	Verify the exact domain independently, then verify the actual dispensing license

Federal law versus FDA enforcement

The FDA states that foreign drugs are generally unapproved in the United States even if they are approved in another country. Importation can also violate labeling and supply-chain requirements. A U.S. prescription proves that a clinician prescribed treatment; it does not authorize a foreign product’s entry.

FDA’s personal-importation policy lists circumstances in which staff may consider a more permissive decision. For serious conditions, those considerations include lack of effective domestic treatment, no promotion to U.S. residents, no unreasonable risk, written affirmation of personal use, and a quantity generally no greater than three months with clinician or treatment documentation.

No factor guarantees admission. The agency explicitly says the policy creates no right or expectation. The detailed guide to whether buying Canadian prescription drugs is legal explains the distinction between prohibition, enforcement discretion and authorized programs.

What changes on October 22, 2026

CBP published an interim final rule suspending the de minimis exemption for international postal shipments and creating postal informal entry. The general effective date is July 24, 2026; October 22 is the compliance date for specified mail provisions.

The rule calls for electronic data and, in relevant cases, an importer of record and customs bond. Drugs also remain subject to FDA requirements. CIPA and pharmacy sellers say this combination will make their established mail model unworkable for most routine orders. That is their operational forecast, not a quotation or conclusion from CBP.

Read what is known—and still unconfirmed—about Canadian pharmacy shipments in 2026 before treating a seller warning as the text of federal law.

Other 2026 developments

S.641, the Safe and Affordable Drugs from Canada Act of 2025, would create a personal-importation framework if enacted. As of September 21, 2026, Congress.gov continued to identify it as pending legislation. It was not current permission to import.

Meanwhile, Section 804 permits FDA-authorized state and tribal wholesale programs. Florida’s proposal was authorized in 2024, and its most recent implementation-deadline extension ran through May 6, 2026. That deadline has now passed; as of September 21, 2026, the program has not shipped any drugs and remains stalled. Such a program requires approved drugs, testing, relabeling, importers and reporting. It is not ordinary online shopping.

The plain-English timeline of 2026 importation rule changes keeps the adopted rule, pending bill and state programs separate.

Insurance and out-of-pocket cost

Canadian mail-order pharmacies generally do not process U.S. insurance at checkout. A patient may receive a receipt and submit a claim, but the plan can deny it because the seller is outside the network, the foreign product is not covered, documentation is missing or the import is not lawful.

Medicare Part D should not be assumed to reimburse a routine foreign order. HSA and FSA rules also present tax issues: IRS guidance generally excludes prescribed drugs imported unlawfully from eligible medical expenses.

Before purchase, ask the insurer for a written answer that identifies the exact drug, seller and shipping arrangement. The insurance guide for Canadian prescription purchases lists the questions and appeal records to keep.

How to assess a Canadian pharmacy

Seller legitimacy and import legality are different. A legitimate licensed pharmacy does not guarantee that U.S. authorities will admit its parcel. Still, verification is essential because rogue sites exploit the price and access concerns that drive cross-border shopping.

Use CIPA’s verifier by entering the exact domain on CIPA’s own site. Do not trust a clickable seal. Then confirm the pharmacy’s legal name, physical address and license in the relevant provincial register. Ask where the specific product will be dispensed; some Canadian services use partner pharmacies in other countries.

Avoid any site that sells prescription medicine without a prescription, hides its location, lacks pharmacist access, offers controlled drugs casually, sends unsolicited advertising or demands irreversible payment. Follow the full Canadian online pharmacy verification checklist.

A safer decision process

Start with the prescriber and a U.S. pharmacist. Ask about an FDA-approved generic, formulary exception, therapeutic alternative, manufacturer assistance, nonprofit program or competitive cash price. Never ration or stop treatment while waiting for international delivery.

If considering a foreign order, check the current FDA and CBP pages near the purchase date. Verify the exact seller and dispensing pharmacy. Obtain written insurance guidance. Read refund and customs terms, and preserve the prescription, invoice and clinician information.

Exercise additional caution with controlled substances, biologics, injectables, compounded products and medicines requiring refrigeration. A delay or temperature excursion can create clinical risk even if a parcel eventually arrives.

Why Canadian and U.S. versions are not automatically interchangeable

Consumers often see the same active ingredient and conclude that the Canadian and American products are legally and clinically identical. The comparison is more complicated. A foreign product can differ in approved indications, labeling, inactive ingredients, packaging, storage instructions, manufacturer or regulated supply chain. Even when the tablets originate from the same facility, the product shipped for a foreign market may not be the FDA-approved product authorized for U.S. distribution.

This distinction is central to federal import law. FDA approval attaches to a specific product and its conditions, not merely to a molecule’s generic name. It is also clinically relevant for modified-release formulations, narrow-therapeutic-index drugs, devices packaged with medicine and products requiring careful temperature control.

A prescriber should review any proposed substitution. Patients should not infer equivalent dosing from similar packaging or a seller’s comparison chart. If a package arrives with a different strength, dosage form, manufacturer or country of origin than ordered, the patient should contact a licensed pharmacist before taking it.

The personal-importation criteria in context

The FDA’s public guidance is sometimes condensed into “personal use plus 90 days equals allowed.” That formula omits the agency’s other considerations and the discretionary nature of the policy. For treatment of a serious condition, the guidance discusses whether effective treatment is unavailable domestically, whether the product is promoted to U.S. residents, whether it presents an unreasonable risk, and whether the consumer provides written personal-use and treatment information.

The quantity is generally no more than a three-month supply. “Generally” and “may consider” matter. They signal a fact-specific enforcement decision, not a license issued in advance. The agency can conclude that a product or shipment does not qualify, even if it contains fewer than 90 days of medicine.

Foreign nationals temporarily visiting the United States have separate FDA guidance concerning medication for their stay. U.S. citizens should not quote that visitor provision as their own mail-order exception. Controlled substances also involve DEA rules, and state possession or prescribing laws can add another layer.

What happens between checkout and delivery

An international prescription order can involve a referral service, dispensing pharmacy, exporter, postal operator, customs broker, importer of record, CBP and FDA. The business collecting payment may not be the pharmacy shown on the parcel. The product may originate outside Canada even when the website is Canadian-owned.

Before shipment, the seller or logistics provider prepares customs and product data. At entry, CBP handles the customs process while FDA can assess drug admissibility. A package can be delayed for missing data, selected for examination, detained for an apparent violation, released or refused. Temperature-sensitive products can be compromised during a delay even if ultimately released.

The October 2026 rule changes the customs stage. It increases the information and entry obligations for postal shipments that previously relied on simplified de minimis treatment. It does not transform the pharmacy into an FDA-approved source, nor does it replace the underlying drug assessment.

Consumers should obtain a tracking number, actual dispensing location, declared product description and written non-delivery terms. A promise that a seller will “handle customs” should be supported by an explanation of the entry method and who bears brokerage, bond or return costs.

State programs do not work like retail websites

Section 804 programs are designed around institutional controls. A state or tribal sponsor submits a proposal. An authorized importer and registered foreign seller participate. Eligible drugs must be identified, tested and relabeled. The sponsor must maintain pharmacovigilance, recall and reporting systems and demonstrate meaningful savings without added public-health risk.

This is why an authorized state program is legally different from a resident ordering the same ingredient from an online pharmacy. The program creates a documented supply chain and FDA oversight. The individual’s retail parcel does not become part of that program merely because the buyer lives in the sponsoring state.

Program announcements also require careful reading. FDA authorization is not necessarily the date medicine becomes available. Product-specific submissions, contracts, testing and distribution steps can follow. Consumers should look for an official state notice identifying eligible participants and launch status rather than assuming that authorization created an immediate public benefit.

Affordability alternatives inside the United States

Cross-border shopping is often driven by a real affordability problem. Before accepting import and delivery uncertainty, compare all lawful domestic prices. The prescriber can check whether a generic, biosimilar, different strength or therapeutically appropriate alternative lowers cost. The insurer can explain preferred tiers, prior authorization, step therapy and formulary-exception procedures.

Manufacturer assistance programs may help eligible uninsured or underinsured patients, although eligibility and covered products vary. Community health centers, nonprofit foundations and disease-specific organizations may identify additional support. Cash-price comparison can reveal that a noninsurance U.S. price is below the copay, but purchases outside the benefit may not count toward the deductible or out-of-pocket maximum.

For Medicare beneficiaries, the plan’s formulary, network pharmacies and formal exception process should be reviewed. A State Health Insurance Assistance Program can provide free counseling without selling a plan. Medicaid beneficiaries should contact their state program before paying cash, because coverage and coordination rules differ.

Affordability work should happen before the current supply runs out. Patients should not split extended-release tablets, change intervals or substitute products without professional guidance. A cheaper acquisition route is not a saving if it causes treatment interruption or an adverse event.

Records to keep

Maintain the prescription, prescriber contact details, order confirmation, itemized invoice, payment record, pharmacy license information, shipment tracking and photographs of the sealed package. Record the product name, strength, manufacturer, lot, expiration date and stated dispensing country when it arrives.

These records support several different needs. A pharmacist can compare the received product with the intended therapy. An insurer can identify what was purchased. A card issuer can evaluate a dispute. FDA or another regulator can investigate a suspected counterfeit or adverse event. Customs correspondence can be answered before its deadline.

Do not alter invoices, understate value or ask a seller to mislabel the contents. A false declaration does not improve legal status and can create additional consequences. If a seller proposes deceptive labeling as a routine service, treat that as a serious warning sign.

Special product categories

Controlled substances should not be approached as ordinary mail-order medicines. DEA authority and strict import restrictions apply. A website that casually offers opioids, stimulants or sedatives without rigorous controls is a red flag.

Biological products, infused drugs and several injected categories are excluded from the Section 804 program rules. That exclusion does not prove that every other import route is available; it illustrates the additional controls these products require. Compounded medicines raise separate questions about the prescriber, ingredients, facility and applicable standards.

Refrigerated medicine presents a practical safety problem. Ask how temperature is monitored, the validated shipping time, acceptable excursion range and replacement policy. A cold pack that arrives warm does not by itself reveal how long the product was outside range. The manufacturer or pharmacist should make the stability assessment.

Products subject to a Risk Evaluation and Mitigation Strategy may require restricted distribution, certified prescribers or monitoring. A foreign transaction can bypass safeguards that are part of safe U.S. use. Patients should discuss these requirements explicitly with the treating clinician.

How to evaluate claims made in advertising

“FDA-approved ingredients,” “same factory,” “licensed in Canada” and “90-day supply” each describe only part of the picture. None alone establishes legal U.S. importation. “No prescription needed” is not convenience; it is a major safety warning for a prescription-only drug.

Testimonials prove neither authenticity nor delivery reliability. Review sites can be manipulated, and a scammer can copy accreditation artwork. Independent verification means leaving the seller’s website, entering the exact domain in a trusted registry and checking the dispensing license with the regulator.

Be cautious when a seller presents a pending bill as current law or describes CIPA’s October forecast as an FDA announcement. A responsible explanation links to the primary document, states its date and clearly labels predictions and commercial policies.

A step-by-step checklist

Before considering an order

• Ask the prescriber about domestic alternatives and the risk of interruption.
• Obtain the exact medicine, strength, dosage form and quantity.
• Check FDA guidance and determine whether DEA rules are relevant.
• Request written insurance and HSA/FSA guidance.
• Compare the true annual domestic and foreign costs.

Before paying

• Verify the exact website domain through CIPA and the dispensing license through the regulator.
• Identify every country and business involved in fulfillment.
• Confirm that a valid prescription is required and a pharmacist is available.
• Read refund, customs, reshipment and temperature-control terms.
• Ask how post-October 22 customs entry will be handled.

When the package arrives

• Check for tampering, damage and temperature problems.
• Match the drug, strength, form, quantity and dispenser to the order.
• Preserve packaging, lot and expiration information.
• Ask a pharmacist about unexplained differences before use.
• Report suspected counterfeit products or adverse events.

This checklist reduces avoidable risk, but it cannot turn a prohibited import into a lawful one or guarantee border release.

Frequently Asked Questions

Can U.S. citizens buy prescription drugs from Canada?

They may be able to place an order, but personal importation of a foreign unapproved drug generally violates federal law and delivery is not guaranteed.

Is it safe if the website says it is Canadian?

The name proves nothing. Verify the exact domain and actual dispensing license independently.

Can I import a 90-day supply?

There is no automatic 90-day exception. Three months is generally the maximum quantity mentioned within limited FDA enforcement considerations.

Will orders be blocked after October 22, 2026?

Pharmacy groups predict most routine mail orders will become unworkable. The official CBP rule creates general customs requirements rather than declaring that every prescription parcel will be blocked.

Does a valid prescription solve the legal issue?

No. It is important medical documentation but does not confer FDA approval or customs admissibility.

Are state importation programs legal?

An FDA-authorized and compliant Section 804 program provides a lawful structured route for eligible drugs. It is not a personal mail-order exception.

Will insurance reimburse the purchase?

Usually not at checkout, and later reimbursement is uncertain. Ask the plan in writing before paying.

Is S.641 already law?

No. It remained pending as of September 21, 2026.

Who makes the final decision at the border?

CBP manages customs entry and FDA assesses drug admissibility, with DEA involvement for controlled substances.

Primary sources

• FDA: Personal Importation
• Federal Register: 2026 CBP postal rule
• Congress.gov: S.641
• FDA: Section 804 policies and authorizations
• CIPA: Verify a Website

This page provides general information as of September 21, 2026. It is not legal or medical advice. Laws, agency practices, insurance terms and shipping operations can change; consult current government sources and qualified professionals for an individual decision.